About: Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic
Source	Medline; PMC
abstract	BACKGROUND: Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged. METHODS: A cross-sectional survey of international uveitis experts was conducted. An expert steering committee identified clinical questions on the use of IMT in patients with NIU during the COVID-19 pandemic. Using an interactive online questionnaire, guided by background experience and knowledge, 139 global uveitis experts generated consensus statements for IMT. In total, 216 statements were developed around when to initiate, continue, decrease and stop systemic and local corticosteroids, conventional immunosuppressive agents and biologics in patients with NIU. Thirty-one additional questions were added, related to general recommendations, including the use of non-steroidal anti-inflammatory drugs (NSAIDs) and hydroxychloroquine. RESULTS: Highest consensus was achieved for not initiating IMT in patients who have suspected or confirmed COVID-19, and for using local over systemic corticosteroid therapy in patients who are at high-risk and very high-risk for severe or fatal COVID-19. While there was a consensus in starting or initiating NSAIDs for the treatment of scleritis in healthy patients, there was no consensus in starting hydroxychloroquine in any risk groups. CONCLUSION: Consensus guidelines were proposed based on global expert opinion and practical experience to bridge the gap between clinical needs and the absence of medical evidence, to guide the treatment of patients with NIU during the COVID-19 pandemic.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1136/bjophthalmol-2020-316776
bibo:pmid	32586933
has license	no-cc
sha1sum (hex)	5ff6d07cf33c5e8470f81a8f3f588b900f9e824d
schema:url	https://doi.org/10.1136/bjophthalmol-2020-316776
resource representing a document's title	Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic
has PubMed Central identifier	PMC7313529
has PubMed identifier	32586933
schema:publication	Br J Ophthalmol
resource representing a document's body	covid:5ff6d07cf33c5e8470f81a8f3f588b900f9e824d#body_text
is schema:about of	named entity 'COVID' named entity 'diflunisal' named entity 'nimesulide' named entity 'intravitreal' named entity 'rheumatologic' named entity 'tissue damage' named entity 'biologics' named entity 'corticosteroid' named entity 'biologics' named entity 'corticosteroids' named entity 'protein' named entity 'case series' named entity 'methylprednisolone' named entity 'industrialised countries' named entity 'corticosteroid therapy' named entity 'IL-6 receptor' named entity 'COX inhibitors' named entity 'rheumatologists' named entity 'TNF' named entity 'inflammation' named entity 'April 2020' named entity 'first-line treatment' named entity 'tocilizumab' named entity 'evidence-based' named entity 'infection' named entity 'COVID' named entity 'signal transduction' named entity 'cytokine storm' named entity 'azathioprine' named entity 'infection' named entity '31 questions' named entity 'systemic therapy' named entity 'physical distancing' named entity 'pregnancy' named entity 'COVID' named entity 'COVID-19' named entity 'uveitis' named entity 'uveitis' named entity 'South America' named entity 'methylprednisolone' named entity 'Italian' named entity 'uveitis' named entity 'Rheumatology' named entity 'COVID' named entity 'COVID-19 pandemic' named entity 'High-risk' named entity 'high-risk' named entity 'pathogen' named entity 'propionates' named entity 'risk factors' named entity 'anti-inflammatory' named entity 'tested positive' named entity 'macrophage inflammatory protein' named entity 'COVID-19' named entity 'corticosteroids' named entity 'plasma' named entity 'infection' named entity 'clinical features' named entity 'corticosteroid' named entity 'inflammatory disease' named entity 'PD1' named entity 'systemic therapy' named entity 'IL-7' named entity 'infection' named entity 'immunosuppressive therapy' named entity 'Th1' named entity 'systemic risk' named entity 'biologics' named entity 'uveitis' named entity 'NSAIDs' named entity 'scleritis' named entity 'naproxen' named entity 'COVID' named entity 'anakinra' named entity 'COVID-19' named entity 'COVID' named entity 'certolizumab' named entity 'systemic therapy' named entity 'South America' named entity 'Hydroxychloroquine' named entity 'risk factors' named entity 'immunosuppression'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software